Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Shuchi Gulati

Hematology Oncology | Hematology | Oncology
UC Davis Health
Regents Of The Univ Of Ca
4501 X St, 
Sacramento, CA 
Clinical Trials:Currently Recruiting for 4 Trials
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
UC Davis Health
Regents Of The Univ Of Ca
4501 X St, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shuchi Gulati is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Gulati is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Head and Neck Squamous Cell Carcinoma (HNSCC), Wilms Tumor, Nephrectomy, and Gastrostomy. Dr. Gulati is currently accepting new patients.

Her clinical research consists of co-authoring 55 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
University Of California Davis Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

REGENTS OF THE UNIV OF CA
4501 X St, Sacramento, CA 95817
Call: 916-734-5959

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Other
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Phase: Phase 1
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Enrollment Status: Recruiting
Publish Date: May 15, 2025
Intervention Type: Drug
Study Drugs: CPI-0209, Irinotecan
Study Phase: Phase 1/Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
Phase 1b/II Trial Combining PD1 Inhibition (Pembrolizumab) and Cesium 131 Brachytherapy With Salvage Surgery to Enhance Immunogenicity and Improve Local Control in Head and Neck Cancer
Phase 1b/II Trial Combining PD1 Inhibition (Pembrolizumab) and Cesium 131 Brachytherapy With Salvage Surgery to Enhance Immunogenicity and Improve Local Control in Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2025
Intervention Type: Device, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 1/Phase 2
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
Enrollment Status: Terminated
Publish Date: April 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Carboplatin, Gemcitabine, Atezolizumab, Docetaxel
Study Phase: Phase 2
View 6 Less Clinical Trials

55 Total Publications

Strategies for Treatment De-escalation in Metastatic Renal Cell Carcinoma.
Strategies for Treatment De-escalation in Metastatic Renal Cell Carcinoma.
Journal: European urology focus
Published: March 28, 2025
View All 55 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Primo N. Lara
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Primo N. Lara
Hematology Oncology | Hematology | Oncology

Regents Of The Univ Of Ca

4501 X St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Primo Lara is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Lara is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David L. Campbell
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David L. Campbell
Hematology Oncology | Hematology | Oncology

Dignity Health Medical Foundation

155 Glasson Way, Suite L 10, 
Grass Valley, CA 
 (51.4 miles away)
530-274-6677
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Campbell is a Hematologist Oncology specialist and a Hematologist in Grass Valley, California. Dr. Campbell is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Gastric Lymphoma, Paget Disease of the Breast, Non-Hodgkin Lymphoma, and Inflammatory Breast Cancer.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Nicholas Mitsiades
Oncology | Endocrinology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Nicholas Mitsiades
Oncology | Endocrinology | Hematology

Regents Of The Univ Of Ca

4501 X St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nicholas Mitsiades is an Oncologist and an Endocrinologist in Sacramento, California. Dr. Mitsiades is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), and Orchiectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gulati's expertise for a condition
ConditionClose
    • Distinguished
    • Renal Cell Carcinoma (RCC)
      Dr. Gulati is
      Distinguished
      . Learn about Renal Cell Carcinoma (RCC).
      See more Renal Cell Carcinoma (RCC) experts
    • Advanced
    • Chromophobe Renal Cell Carcinoma
      Dr. Gulati is
      Advanced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Gulati is
      Advanced
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Familial Wilms Tumor 2
      Dr. Gulati is
      Advanced
      . Learn about Familial Wilms Tumor 2.
      See more Familial Wilms Tumor 2 experts
    • Head and Neck Squamous Cell Carcinoma (HNSCC)
      Dr. Gulati is
      Advanced
      . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
      See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
    • Wilms Tumor
      Dr. Gulati is
      Advanced
      . Learn about Wilms Tumor.
      See more Wilms Tumor experts
    • WT1-Related Wilms Tumor Syndromes
      Dr. Gulati is
      Advanced
      . Learn about WT1-Related Wilms Tumor Syndromes.
      See more WT1-Related Wilms Tumor Syndromes experts
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Gulati is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Bladder Cancer
      Dr. Gulati is
      Experienced
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Choriocarcinoma
      Dr. Gulati is
      Experienced
      . Learn about Choriocarcinoma.
      See more Choriocarcinoma experts
    • Familial Prostate Cancer
      Dr. Gulati is
      Experienced
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Gastrostomy
      Dr. Gulati is
      Experienced
      . Learn about Gastrostomy.
      See more Gastrostomy experts
    • Lung Cancer
      Dr. Gulati is
      Experienced
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved